Neurocrine Biosciences | NBIX - 貿易債務者





貿易債務者 変化する 日付
AbbVie USD 12.59B 180M 2025-12
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
ALKERMES USD 334.02M 21.08M 2025-12
Alnylam Pharmaceuticals USD 777.57M 187.2M 2025-12
Amgen USD 9.57B 1.08B 2025-12
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 908.21M 117.95M 2025-12
Cytokinetics USD 1.81M 6.6M 2025-09
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Exelixis USD 286.92M 24.38M 2025-12
Gilead Sciences USD 4.91B 182M 2025-12
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
Incyte USD 1.05B 27.09M 2026-03
Ionis Pharmaceuticals USD 74M 8M 2026-03
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Pfizer USD 18.12B 2.02B 2025-09
Prothena USD 5.16M 0 2023-12
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Repligen USD 158.59M 9.62M 2025-12
Rigel Pharmaceuticals USD 28.9M 1.39M 2024-06
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Teva Pharmaceutical Industries USD 3.39B 316M 2026-03
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
Vertex Pharmaceuticals USD 2.05B 106.4M 2025-12
Xoma USD 14.78M 4.96M 2024-06